Aurinia will explore possible sale, following push by shareholder
Aurinia Pharmaceuticals said it will start exploring strategic alternatives, including a potential sale. The announcement follows calls by one of its major shareholders, MKT Capital.
“The board will consider a wide range of options for the company including, but not limited to, a potential sale, merger, or other strategic transaction,” Aurinia said in a press release Thursday. It also said that two board directors, chair George Milne and Joseph Hagan, were resigning after failing to win majority support from shareholders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.